Summit Therapeutics (SMMT) Enterprise Value (2017 - 2026)
Summit Therapeutics' (SMMT) quarterly Enterprise Value came in at -$690.7 million in Q2 2026, down 131.62% YoY from $2.2 billion in Q2 2025, and down 15.36% on a QoQ basis from -$598.7 million in Q1 2026.
Summit Therapeutics (SMMT) Enterprise Value (2017 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has 10 years of Enterprise Value data on file, last reported at -$690.7 million in Q2 2026.
- Quarterly Enterprise Value fell 131.62% year-over-year to -$690.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$690.7 million (down 131.62% YoY) and the FY2025 annual result came in at -$713.4 million, down 73.02% from the prior year.
- Enterprise Value retreated to -$690.7 million in Q2 2026, from -$598.7 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$28.8 million in Q2 2024 to a low of -$713.4 million in Q4 2025.
- A 5-year average of -$302.9 million and a median of -$226.9 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2023 — Enterprise Value jumped 88.99% — and 2025, when it sank 937.04%.
- Tracing SMMT's Enterprise Value over 5 years: stood at -$648.6 million in 2022, then jumped by 88.99% to -$71.4 million in 2023, then plunged by 477.32% to -$412.3 million in 2024, then sank by 73.02% to -$713.4 million in 2025, then rose by 3.19% to -$690.7 million in 2026.
- The last three Enterprise Value figures came in at -$690.7 million (Q2 2026), -$598.7 million (Q1 2026), and -$713.4 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | -690.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -690.68 Mn |
| Mar 31, 2026 | -598.73 Mn |
| Dec 31, 2025 | -713.45 Mn |
| Sep 30, 2025 | -238.88 Mn |
| Jun 30, 2025 | -298.19 Mn |
| Mar 31, 2025 | -211.84 Mn |
| Dec 31, 2024 | -412.35 Mn |
| Sep 30, 2024 | -94.10 Mn |
| Jun 30, 2024 | -28.75 Mn |
| Mar 31, 2024 | -61.61 Mn |
| Dec 31, 2023 | -71.43 Mn |
| Sep 30, 2023 | -198.95 Mn |
| Jun 30, 2023 | -215.01 Mn |
| Mar 31, 2023 | -241.93 Mn |
| Dec 31, 2022 | -648.61 Mn |
| Sep 30, 2022 | -121.97 Mn |
| Dec 31, 2021 | -71.79 Mn |
| Jun 30, 2021 | -103.40 Mn |
| Mar 31, 2021 | -102.20 Mn |
| Dec 31, 2020 | -66.42 Mn |